Acharya, R., Zeng, X., & Upadhyay, K. (2023). Synthetic cannabinoid-associated acute interstitial nephritis: An emerging cause of pediatric acute kidney injury? Clinical Nephrology. Case Studies, 11, 55.

PubMed  PubMed Central  Google Scholar 

Adamowicz, P., Gieroń, J., Gil, D., Lechowicz, W., Skulska, A., & Tokarczyk, B. (2017). The effects of synthetic cannabinoid UR-144 on the human body—a review of 39 cases. Forensic Science International, 273, e18–e21.

Article  PubMed  Google Scholar 

Alves, V. L., Gonçalves, J. L., Aguiar, J., Teixeira, H. M., & Câmara, J. S. (2020). The synthetic cannabinoids phenomenon: From structure to toxicological properties. A Review. Critical Reviews in Toxicology, 50(5), 359–382.

Article  PubMed  Google Scholar 

Alzu’bi, A., Almahasneh, F., Khasawneh, R., Abu-El-Rub, E., Baker, W. B., & Al-Zoubi, R. M. (2024). The synthetic cannabinoids menace: A review of health risks and toxicity. European Journal of Medical Research, 29(1), 49.

Article  PubMed  PubMed Central  Google Scholar 

American Psychiatric Association. (2022). Substance-related and addictive disorders. In Diagnostic and Statistical Manual of Mental Disorders Fifth Edition, Text Revision (DSM-5-TR) (5th ed.). https://doi.org/10.1176/appi.books.9780890425787.x16_Substance_Related_Disorder. Accessed 15 Nov 2024.

Anthony, J. C., & Petronis, K. R. (1995). Early-onset drug use and risk of later drug problems. Drug and Alcohol Dependence, 40(1), 9–15.

Article  PubMed  Google Scholar 

Appiah-Kusi, E., Leyden, E., Parmar, S., Mondelli, V., McGuire, P., & Bhattacharyya, S. (2016). Abnormalities in neuroendocrine stress response in psychosis: The role of endocannabinoids. Psychological Medicine, 46(1), 27–45.

Article  PubMed  Google Scholar 

Ashton, J. C. (2012). Synthetic cannabinoids as drugs of abuse. Current Drug Abuse Reviews, 5(2), 158–168.

Article  PubMed  Google Scholar 

Assi, S., Marshall, D., Bersani, F. S., & Corazza, O. (2020). Uses, effects and toxicity of synthetic cannabinoids from the perspective of people with lived experiences. Journal of Psychoactive Drugs, 52(3), 237–247.

Article  PubMed  Google Scholar 

Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009). ‘Spice’and other herbal blends: Harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44(5), 832–837.

Article  PubMed  Google Scholar 

Bahji, A., & Mazhar, M. N. (2016). Treatment of cannabis dependence with synthetic cannabinoids: A systematic review. Canadian Journal of Addiction, 7(4), 8–13.

Google Scholar 

Bassir Nia, A., Medrano, B., Perkel, C., Galynker, I., & Hurd, Y. L. (2016). Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. Journal of Psychopharmacology, 30(12), 1321–1330.

Article  PubMed  Google Scholar 

Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670.

Article  PubMed  Google Scholar 

Bhat, T. A., Kalathil, S. G., Goniewicz, M. L., Hutson, A., & Thanavala, Y. (2023). Not all vaping is the same: Differential pulmonary effects of vaping cannabidiol versus nicotine. Thorax, 78(9), 922–932.

Article  PubMed  Google Scholar 

Boileau-Falardeau, M., Contreras, G., Garipy, G., & Laprise, C. (2022). Patterns and motivations of polysubstance use: A rapid review of the qualitative evidence. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 42(2), 47.

Article  PubMed  Google Scholar 

Brezing, C. A., & Levin, F. R. (2018). The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology, 43(1), 173–194.

Article  PubMed  Google Scholar 

Brown, J. D., Rivera Rivera, K. J., Hernandez, L. Y. C., Doenges, M. R., Auchey, I., Pham, T., & Goodin, A. J. (2021). Natural and synthetic cannabinoids: Pharmacology, uses, adverse drug events, and drug interactions. The Journal of Clinical Pharmacology, 61, S37–S52.

Article  PubMed  Google Scholar 

Bukke, V. N., Archana, M., Villani, R., Serviddio, G., & Cassano, T. (2021). Pharmacological and toxicological effects of phytocannabinoids and recreational synthetic cannabinoids: Increasing risk of public health. Pharmaceuticals, 14(10), 965.

Article  PubMed  PubMed Central  Google Scholar 

Burgess, A., Hays, H. L., Badeti, J., Spiller, H. A., Rine, N. I., Gaw, C. E., Ding, K., & Smith, G. A. (2024). Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America’s Poison Centers. Clinical Toxicology, 62(4), 256–266.

Article  PubMed  Google Scholar 

Busardò, F. P., & Zaami, S. (2022). Current design of new psychoactive substances. Current Pharmaceutical Design, 28(15), 1211–1212.

Article  PubMed  Google Scholar 

Cannaert, A., Sparkes, E., Pike, E., Luo, J. L., Fang, A., Kevin, R. C., Ellison, R., Gerona, R., Banister, S. D., & Stove, C. P. (2020). Synthesis and in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4f-mdmb-bica, 5f-mpp-pica, mmb-4en-pica, cumyl-cbmica, adb-binaca, app-binaca, 4f-mdmb-binaca, mdmb-4en-pinaca, a-chminaca, 5f-ab-p7aica, 5f-mdmb-p7aica, and 5f-ap7aica. ACS Chemical Neuroscience, 11(24), 4434–4446.

Article  PubMed  Google Scholar 

Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014). Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12–41.

Article  PubMed  Google Scholar 

Castellanos, D., Singh, S., Thornton, G., Avila, M., & Moreno, A. (2011). Synthetic cannabinoid use: A case series of adolescents. Journal of Adolescent Health, 49(4), 347–349.

Article  Google Scholar 

Center for Behavioral Health Statistics and Quality. (2023). 2022 national survey on drug use and health public use file codebook. Rockville, MD: Substance Abuse and Mental Health Services Administration, Retrieved from https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2022/NSDUH-2022-datasets/NSDUH-2022-DS0001/NSDUH-2022-DS0001-info/NSDUH-2022-DS0001-info-codebook.pdf. Accessed 15 Nov 2024.

Chiu, V., Leung, J., Hall, W., Stjepanović, D., & Degenhardt, L. (2021). Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology, 193, 108610.

Article  PubMed  Google Scholar 

Clayton, H. B., Lowry, R., Ashley, C., Wolkin, A., & Grant, A. M. (2017). Health risk behaviors with synthetic cannabinoids versus marijuana. Pediatrics, 139(4), 1-10. 

Clements-Nolle, K., Lensch, T., Larson, S., & Yang, W. (2016). Prevalence and correlates of any and frequent synthetic cannabinoid use in a representative sample of high school students. Substance Use & Misuse, 51(9), 1139–1146.

Article  Google Scholar 

Coccini, T., De Simone, U., Lonati, D., Scaravaggi, G., Marti, M., & Locatelli, C. (2021). Mam-2201, one of the most potent—naphthoyl indole derivative—synthetic cannabinoids, exerts toxic effects on human cell-based models of neurons and astrocytes. Neurotoxicity Research, 39(4), 1251–1273.

Article  PubMed  Google Scholar 

Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021). Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 7(1), 16.

Article  PubMed  PubMed Central  Google Scholar 

Cooke, M. E., Potter, K. W., Jashinski, J., Pascale, M., Schuster, R. M., Tervo-Clemmens, B., Hoeppner, B. B., Pachas, G. N., Evins, A. E., & Gilman, J. M. (2023). Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership. Frontiers in Psychiatry, 14, 1083334.

Article  PubMed  PubMed Central  Google Scholar 

Cooper, Z. D. (2016). Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Current Psychiatry Reports, 18, 1–10.

Article  Google Scholar 

Craft, S., Austin, A., Tooth, T., Glover, C., Garrett, T., Blagbrough, I. S., Sunderland, P., Pudney, C. R., & Freeman, T. P. (2023). Synthetic cannabinoid use in an adult male prison in the UK. International Journal of Drug Policy, 122, 104219.

Article  PubMed  Google Scholar 

Craft, S., Sunderland, P., Millea, M. F., Pudney, C. R., Sutcliffe, O. B., & Freeman, T. P. (2024). Detection and quantification of synthetic cannabinoids in seven illicitly sourced disposable vapes submitted by an individual presenting to a UK drug and alcohol service. Addiction.

D’Amico, E. J., Rodriguez, A., Tucker, J. S., Pedersen, E. R., & Shih, R. A. (2018). Planting the seed for marijuana use: Changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. Drug and Alcohol Dependence, 188, 385–391.

Article  PubMed  PubMed Central  Google Scholar 

Darke, S., Duflou, J., Farrell, M., Peacock, A., & Lappin, J. (2020). Characteristics and circumstances of synthetic cannabinoid-related death. Clinical Toxicology, 58(5), 368–374.

Article  PubMed  Google Scholar 

Das, A., Hendershot, C. S., Husain, M. I., Knyahnytska, Y., Elsaid, S., Le Foll, B., & Kloiber, S. (2024). Perceptions, experiences, and patterns of cannabis use in individuals with mood and anxiety disorders in the context of Cannabis Legalization and Medical Cannabis Program in Canada–a qualitative study. Pharmacopsychiatry, 57(03), 141–151.

Article  PubMed  Google Scholar 

Dawson, D., Stjepanovic, D., Lorenzetti, V., Cheung, C., Hall, W., & Leung, J. (2024). The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis. Drug and alcohol dependence, 257, 111263

de Oliveira, M. C., Vides, M. C., Lassi, D. L. S., Torales, J., Ventriglio, A., Bombana, H. S., Leyton, V., Périco, C. D. A. M., Negrão, A. B., & Malbergier, A. (2023). Toxicity of synthetic cannabinoids in K2/spice: A systematic review. Brain Sciences, 13(7), 990.